Last €52.04 EUR
Change Today +0.04 / 0.08%
Volume 336.1K
DSM On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
OTC US
As of 9:11 AM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

koninklijke dsm nv (DSM) Snapshot

Open
€52.00
Previous Close
€52.00
Day High
€52.21
Day Low
€51.92
52 Week High
11/25/13 - €59.44
52 Week Low
10/16/14 - €43.61
Market Cap
9.4B
Average Volume 10 Days
661.3K
EPS TTM
€1.72
Shares Outstanding
181.4M
EX-Date
08/6/14
P/E TM
30.3x
Dividend
€1.70
Dividend Yield
3.27%
Current Stock Chart for KONINKLIJKE DSM NV (DSM)

Related News

No related news articles were found.

koninklijke dsm nv (DSM) Related Businessweek News

View More BusinessWeek News

koninklijke dsm nv (DSM) Details

Koninklijke DSM N.V. operates as a life sciences and materials sciences company worldwide. The company operates in five segments: Nutrition, Pharma, Performance Materials, Polymer Intermediates, and Innovation Center. It manufactures food enzymes, cultures, savory ingredients, and other specialties, as well as nutritional products, such as vitamins, carotenoids, eubiotics, feed enzymes, premixes, nutritional lipids, and cultures for the food and beverage, feed, personal care, dietary supplements, and pharmaceutical industries. The company also provides custom manufacturing and development services to the pharmaceutical, biopharmaceutical, and agrochemical industries; and beta-lactam active pharmaceutical ingredients, such as semi-synthetic penicillins and semi-synthetic cephalosporins, as well as nystatin. In addition, it offers engineering thermoplastic solutions; Dyneema, a strong fiber; and resins solutions for paints and coatings, composite materials, and optical fiber coatings. Further, the company produces caprolactam and acrylonitrile that are raw materials for synthetic fibers and plastics; and other products, including ammonium sulfate, sodium cyanide, cyclohexanone, and diaminobutane. Additionally, it develops materials-based solutions comprising coatings, drug delivery platforms, and a range of biomedical materials for medical device and biopharmaceutical industries; creates solutions for bioconversion of feedstocks for the production of bio-energy, such as cellulosic biofuels, as well as bio-based chemicals and materials; and provides smart coatings and surface technologies to the solar industry. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

21,477 Employees
Last Reported Date: 11/4/14
Founded in 1902

koninklijke dsm nv (DSM) Top Compensated Officers

Chairman of Managing Board, Chief Executive O...
Total Annual Compensation: €1.4M
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €902.0K
Member of The Managing Board
Total Annual Compensation: €954.0K
Member of Managing Board
Total Annual Compensation: €887.0K
Member of The Managing Board
Total Annual Compensation: €268.0K
Compensation as of Fiscal Year 2013.

koninklijke dsm nv (DSM) Key Developments

Royal DSM Reports Earnings Results for the Third Quarter and Nine Months Ended September 2014; Provides Earnings Guidance for the Year 2014

Royal DSM reported earnings results for the third quarter and nine months ended September 2014. For the quarter, the company reported net sales of EUR 2,323 million compared to EUR 2,354 million a year ago. Net sales from continuing operations were EUR 2,323 million compared to EUR 2,213 million a year ago. EBITDA was EUR 315 million compared to EUR 343 million a year ago. EBITDA from continuing operations was EUR 315 million compared to EUR 331 million a year ago. Core net profit was EUR 141 million or EUR 0.81 per share compared to EUR 146 million or EUR 0.84 per share a year ago. Net profit before exceptional items, continuing operations was EUR 121 million or EUR 0.69 per share compared to EUR 134 million or EUR 0.76 per share a year ago. Net profit after exceptional items was EUR 93 million or EUR 0.51 per share compared to EUR 117 million or EUR 0.65 per share a year ago. Cash flow from operations was EUR 301 million compared to EUR 320 million a year ago. Capital expenditures were EUR 138 million compared to EUR 138 million a year ago. Net debt was EUR 2,479 million compared to EUR 1,841 million a year ago. For the nine months, the company reported EBITDA of EUR 878 million compared to EUR 996 million a year ago. EBITDA from continuing operations was EUR 880 million compared to EUR 964 million a year ago. Core net profit was EUR 380 million or EUR 2.20 per share compared to EUR 431 million or EUR 2.51 per share a year ago. Net profit before exceptional items, continuing operations was EUR 330 million or EUR 1.90 per share compared to EUR 396 million or EUR 2.27 per share a year ago. Net profit after exceptional items was EUR 252 million or EUR 1.41 per share compared to EUR 348 million or EUR 1.98 per share a year ago. Cash flow from operations was EUR 390 million compared to EUR 522 million a year ago. Capital expenditures were EUR 406 million compared to EUR 438 million a year ago. Full year 2014 outlook in line with current market expectations.

DSM To Sale Or Spin-off Low performing Units

Koninklijke DSM N.V. (ENXTAM:DSM) intends to sell or spin off lower-performing units. The company said it is prepared to sell or spin off into joint ventures its composite resins and polymer intermediates businesses. "All three businesses do not fit with the resilient portfolio that DSM is building. We want to reduce our cyclicality and those three businesses are all less performing or have a cyclical character," Feike Sijbesma, Chief Executive Officer, said. DSM shares rose 3%.

Evonik Reportedly Eyes DSM

Evonik Industries AG (DB:EVK) intends to acquire Koninklijke DSM N.V. (ENXTAM:DSM), Bloomberg reported, citing sources in the know. Evonik is holding talks with the advisors regarding a potential deal with DSM which would create a company with €22 billion in annual revenue. Other takeover options are also under consideration, the sources said. Evonik would be buying the whole company, however, is mainly interested in the Nutrition unit. As per the insiders, a partial acquisition of DSM is also possible or the takeover of the whole firm, after which certain units will be sold. Evonik has not yet decided to make a new takeover attempt, the sources said. Based on DSM's shareholder structure, an acquisition requires the support of the group's Board of Directors. Evonik, in addition to DSM, is also eyeing Croda International plc (LSE:CRDA) and Clariant AG (SWX:CLN). SeeNews added that spokesperson for Evonik denied plans to buy DSM and said there were not any talks ongoing while DSM declined to comment when contacted by the news agency.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSM:NA €52.04 EUR +0.04

DSM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grupo Bimbo SAB de CV $39.42 MXN +0.39
Huntsman Corp $26.67 USD +0.32
Kerry Group PLC €56.30 EUR -0.28
Merck KGaA €78.58 EUR +0.07
Solvay SA €110.85 EUR +0.25
View Industry Companies
 

Industry Analysis

DSM

Industry Average

Valuation DSM Industry Range
Price/Earnings 66.8x
Price/Sales 1.0x
Price/Book 1.5x
Price/Cash Flow 46.0x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE DSM NV, please visit www.dsm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.